Skip to main content
  • About Us
  • Image Credits
  • Contributor Info
  • RSS
  • Log In
  • Join
  • TwitterTwitter
  • E-Alerts
  • Visit StemJournal

Main menu

  • About
    • Image Credits
    • Contributor Info
    • E-Alerts
  • Chapters
    • Cellular and nuclear reprogramming
    • Ectoderm specification and differentiation
    • Endoderm specification and differentiation
    • Epigenetics
    • Genomics and proteomics
    • Germ cell and somatic stem cell biology in reproduction
    • Manufacturing
    • Mesoderm specification and differentiation
    • Niche biology, homing, and migration
    • Renewal
    • Stem cell immunology
    • Therapeutic prospects
    • Tissue engineering
  • Protocols
    • Ectoderm differentiation
    • Endoderm differentiation
    • Genome editing
    • Mesoderm differentiation
    • Pluripotent stem cells
    • PSC characterization
    • PSC genetic stability
    • Reprogramming
  • StemLabs
    • Stem Cell COREdinates
    • Core Facility Profiles
      • Boston Children's Hospital Human Neuron Core
      • Boston University Center for Regenerative Medicine iPSC Core
      • Columbia Stem Cell Initiative Stem Cell Core Facility
      • Harvard Stem Cell Institute iPS Core Facility
    • Stem Cell Protocols
    • Stem Cell Reagents
    • Other Resources
  • News & Profiles
    • Latest News
    • Stem Cell Institute Profiles
  • Journal Stream
  • Forum

    Search form

    You are here

    Home

    Biblio

    Author Title Type [ Year(Asc)]
    Filters: Author is Solomon, Scott R  [Clear All Filters]
    2020
    Solomon SR, Aubrey MT, Zhang X, Jackson KC, Morris LE, H Holland K, Solh MM, Bashey A. Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide. Blood Adv. 2020;4(20):5311-5321.
    • PubMed
    • Google Scholar
    Solomon SR, St Martin A, Zhang M-J, Ballen K, Bashey A, Battiwalla M, Baxter-Lowe LAnn, Brunstein C, Chhabra S, Perez MAngel Diaz, et al. Optimal donor for African Americans with hematologic malignancy: HLA-haploidentical relative or umbilical cord blood transplant. Biol Blood Marrow Transplant. 2020.
    • PubMed
    • Google Scholar
    Solomon SR, Solh M, Zhang X, Brown S, Jackson KC, H Holland K, Morris LE, Bashey A. Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplant. Blood Adv. 2020;4(15):3669-3676.
    • PubMed
    • Google Scholar
    Solh MM, Speckhart D, Solomon SR, Bashey A, Morris LE, Zhang X, H Holland K. The Transplant Evaluation Rating Scale predicts overall survival after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2020;4(19):4812-4821.
    • PubMed
    • Google Scholar
    2016
    Solomon SR, Solh M, Morris LE, H Holland K, Bashey A. Myeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant Cyclophosphamide. Adv Hematol. 2016;2016:9736564.
    • PubMed
    • Google Scholar

    Disclaimer | Privacy Policy | StemBook is published by IOS Press, Copyright © 2021
    Copyright 2013 by the Massachusetts General Hospital. Some sections copyright 2008–2009 by The President and Fellows of Harvard College.

    IOS Press logoHSCI logoNIH logoMIND logo


    Creative Commons License
    All content unless otherwise noted is licensed under a Creative Commons Attribution 3.0 Unported License